Home Stock

Stock Research: AbCellera Biologics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

AbCellera Biologics

NSQ:ABCL CA00288U1066
46
  • Value
    10
  • Growth
    40
  • Safety
    Safety
    89
  • Combined
    25
  • Sentiment
    61
  • 360° View
    360° View
    46
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

more

ANALYSIS: With an Obermatt 360° View of 46 (better than 46% compared with alternatives), overall professional sentiment and financial characteristics for the stock AbCellera Biologics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for AbCellera Biologics. The consolidated Sentiment Rank has a good rank of 61, which means that professional investors are more optimistic about the stock than for 61% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 89 or better than 89% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 10, meaning that the share price of AbCellera Biologics is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 40. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Safety
Country Canada
Industry Life Sciences Tools & Services
Size Small
Website abcellera.com
Index
NASDAQ
AbCellera Biologics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
10 38 33 89
Growth
40 73 51 3
Safety
Safety
89 100 100 98
Sentiment
61 80 42 85
360° View
360° View
46 77 74 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
72 80 73 65
Opinions Change
89 50 50 50
Pro Holdings
n/a 60 38 97
Market Pulse
6 46 36 54
Sentiment
61 80 42 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
10 38 33 89
Growth
40 73 51 3
Safety Safety
89 100 100 98
Combined
25 50 74 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
3 5 5 17
Price vs. Earnings (P/E)
67 93 93 95
Price vs. Book (P/B)
63 83 70 88
Dividend Yield
1 1 1 1
Value
10 38 33 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
6 98 98 1
Profit Growth
13 17 4 56
Capital Growth
73 80 67 42
Stock Returns
86 45 23 3
Growth
40 73 51 3
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
71 100 100 70
Refinancing
79 79 77 71
Liquidity
59 95 95 100
Safety Safety
89 100 100 98

Similar Stocks

Discover high‑ranked alternatives to AbCellera Biologics and broaden your portfolio horizons.

Fairfax India Holdings

TOR:FIH.U
Country: Canada
Industry: Asset Management & Custody
Size: Medium
Full Stock Analysis

Linamar

TOR:LNR
Country: Canada
Industry: Auto Parts & Equipment
Size: Large
Full Stock Analysis

Equinox Gold

ASQ:EQX
Country: Canada
Industry: Gold Production
Size: Medium
Full Stock Analysis

Parex Resources

TOR:PXT
Country: Canada
Industry: Oil & Gas Production
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews